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A clinical study of anti-NDP in the sera of patients in a large
repetitive hemodialysis program. Anti-NDP has been detected in the
sera of 38 of 430 patients on regular hemodialysis at the Regional
Kidney Disease Program in Minneapolis. It developed in these
patients from 7 to 58 months after commencement of dialysis.
Bacterial infection appeared temporally related to the development
of anti-NDP in 12 patients. Hemolytic episodes, possibly related to
anti-NOP, occurred in Il. Fifty-five percent of the patients never
reused dialyzers. The antibody preceded the insertion of a bovine
graft in seven. We postulate that anti-N is recognizing an anti-
genie site similar to that recognized by Vicia graminea lectin, and
that this site might become immunogenic by alteration of M and N
antigens on red blood cell surfaces. Though formaldehyde might
be involved in this alteration, dialysis membrane reuse does not
seem to be required for the formation of anti-N0.
Etude clinique de I'anti-NDP dana serum de malades dana le cadre
d'un programme de'hémodialyse. L'anti - N0 a été détecté dans Ic
serum de 38 parmi 430 malades en hémodialyse pCriodique au
Regional Kidney Disease Program a Minneapolis. II est apparu
chez ces malades de 7 a 58 mois apres Ic debut de l'hCmodialyse.
Des infections bactériennes paraissent liées daus Ic temps au déve-
loppement de l'anti - NDP chez 12 malades. Des crises hCmoly-
tiques, peut-etre liées a l'anti-NDP, sont survenues chez 11 malades.
55% des malades n'ont jamais rCutilisé les dialyseurs. L'apparition
de l'anticorps a précédé Ia misc en place d'un greffon bovin chez 7
malades. Nons supposons que l'anti-NDP reconnait un site antigé-
nique similaire a celui reconnu par Ia lectine de la graminée Vincia
et que ce site peut devenir immunogCnique par Ia modification des
antigCnes M et N a Ia surface des hCmaties. Bien que Ia formal-
déhyde puisse jouer un role dans cette modification, il nesemble
pas que Ia rCutilisation d'une membrane de dialyse soit in-
dispensable pour Ia formation de I'anti-Nu.
In routine blood banking practice, anti-N is a very
rare antibody. In patients without chronic disease,
anti-N is frequently an autoantibody [1—3]. Although
occasionally found in healthy blood donors without
evidence of adverse effects related to the presence of
the antibody [IJ, spontaneously developing auto anti-
N has been implicated as a cause of hemolytic anemia
in three cases [2,4,5]. Three recent studies have re-
ported the development of antibodies with specificity
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similar to anti-N in patients with chronic renal failure
treated with regular hemodialysis [6—8]. In these
patients, the antibody developed after variable peri-
ods of time on dialysis and was not usually associated
with in vivo hemolysis. It was detected more fre-
quently in patients reusing their dialysis membranes
[7,9], suggesting a causal relationship. Some observ-
ers have suggested that the use of formaldehyde ster-
ilization after dialysis might alter the MN antigens of
residual red blood cells in the dialyzer in such a way
that the N antigen becomes immunogenic [6,7].
This article describes the clinical and serological
characteristics of 38 patients treated by regular hemo-
dialysis at the Regional Kidney Disease Program in
Minneapolis in whom an antibody reacting similarly
to anti-N was detected between 1971 and 1975. Since
the antibody developing in dialysis patients may have
a different specificity than the iso or auto anti-N
occurring in other conditions, we will refer to this
antibody as anti-NDP in this paper.
Patients and methods
Patients accepted for repetitive hemodialysis were
dialyzed either in the Limited Care Facility (LCF) in
Minneapolis, in satellite units or by home dialysis.
Blood access was obtained by Scribner shunts, simple
arteriovenous fistulae, or by the implantation of a
bovine carotid artery in the forearm [10]. Patients
treated in the LCF utilized the Kiil dialyzer and its
modifications throughout. A solution of 3% formal-
dehyde was used for membrane sterilization. Patients
in the satellite units and on home dialysis utilized the
Kill dialyzer and its modifications until it was re-
placed by the Dow 4 hollow fiber kidney in October,
1972, for home dialysis patients and in 1973 for
patients in satellite units. Two home dialysis patients
used a Kill dialyzer throughout the time that they
were receiving dialysis. Dialyzers were reused only by
home dialysis patients, both the Kiil and the Dow 4
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dialyzers being sterilized with 4% formalin solution.
The majority of patients had red blood cell antigen
phenotyping performed before the initiation of
dialysis provided they had not received recent blood
transfusions. They also were screened for the pres-
ence of unexpected antibodies. After initial screening
patients were retested either when hospitalized for
complications, or when they required transfusions.
Screening procedures were performed either at Hen-
nepin County Medical Center (HCMC) or War Me-
morial Blood Bank (WMBB). Periodic screening on a
regular basis was not performed.
The screening of patients for the presence of unex-
pected antibodies was performed by standard blood
bank procedures, using saline phase incubation at
room temperature, albumin phase incubation at
37°C, and anti-human globulin (Coombs) phase.
When the screening cells were positive, panels con-
taining eight to ten cells were tested to define the
pattern of reactivity of the antibody.
Red blood cell survival studies were performed
using standard 51Cr labeling techniques. For survival
studies of the patient's own cells, 25 ml of blood was
mixed with 75 tCi of Na2 51Cr 04 at 37°C for 30 mm.
For survival studies of donor cells, 10 ml of blood
was mixed with 30 tCi of Na2 51Cr 04 at 37°C for 30
mm. After the incubation, 10 to 50 mg of ascorbic
acid was mixed with the cells. An aliquot (20 ml for
auto survivals and 2 to 3 ml for donor blood surviv-
als) was injected intravenously into the patient and a
second aliquot used to make the standard. Blood was
sampled from the patient 30 mm later and daily for
five to eight days. Red blood cell radioactivity was
determined on each sample using an automatic
gamma counter (Searle, model 1085).
Results
Between 1971 and 1975, 430 patients treated by
regular hemodialysis were screened for the presence
of anti-NDP either at HCMC or WMBB, at least once
during this period. Anti-ND? was detected in 38
patients (8.8%), 24 women and 14 men (Table 1). The
mean age of women was 53 yr (range, 35 to 68 yr) and
the mean age of the men was 51 yr (range, 22 to 72
yr). In 34 of the 38 patients, red blood cell phe-
notypes were obtained at the institution of regular
hemodialysis when they had not recently been trans-
fused. The distribution of MN phenotypes among
these is shown in Table 2. Five of the 38 patients had
no transfusions or pregnancies prior to development
of Anti-ND?. Twenty-four percent of the patients de-
veloping anti-ND? had polycystic kidney disease com-
pared to an incidence of 9.9% in the total program.
The mean duration of dialysis at the time at which
anti-ND? developed was 20 months (range, 7 to 58
months). In most patients the time at which anti-ND?
developed could be established precisely, since
monthly serum samples for HB8Ag testing had been
frozen and were available for retrospective screening.
In 15 patients antibody screening procedures were
repeated several times, and there was evidence of
persistence of the antibody from 3 to 42 months.
Nineteen patients had a bovine fistula in situ for at
least part of the time that they were treated by hemo-
dialysis. Because of the possibility of the bovine fis-
tulae introducing a foreign N-like antigen, the devel-
opment of anti-ND? in relation to placement of a
bovine fistula was carefully documented. In seven
patients anti-ND p was present prior to insertion of a
bovine fistula. One patient had a bovine fistula in
place for 14 months without developing anti-ND?.
One year after removal of the graft, she developed the
antibody.
Five patients received kidney transplants. In one
individual (patient 7) the graft functioned well for 28
months. The titer of anti-ND? dropped from 1:8 at the
time of transplantation to undetectable levels during
the ensuing 12 months, and anti-NDP has not been
found since. In two other patients the antibody per-
sisted throughout the time the graft functioned, one
patient dying after three months as the result of sep-
sis, and the second patient rejecting his graft within
two months. In patient 24 the titer of anti-ND? had
dropped from 1:32 at transplantation to 1:4 five
months later (Fig. 1).
Twenty-two patients (Table 3) with antibody (5 5%)
had never reused dialyzers at any time. Of these, 18
had dialyzed in the LCF using Kiil dialyzers and 4
patients dialyzed in satellite units. Of the remaining
16 patients (45%) who reutilized their dialyzers, 13
were receiving home dialysis at the time that they
developed anti-NDP, and one was in home training.
One individual (patient 15) had been in home train-
ing for two months in 1971 before being transferred
to a satellite unit. Anti-ND? was absent from his
serum in September, 1973, but appeared in December,
1973 (Fig. 2). The final patient in this group (35) was
receiving home dialysis using a Dow 4 dialyzer for six
months before transferring to a satellite unit where
anti-ND? developed. Patient 3 was in the home train-
ing unit at the time of developing anti-ND? and was
dialyzed at home for two months before being trans-
ferred to the LCF. The antibody persisted for the
ensuing 34 months (Fig. 3) and increased in titer.
Serious bacterial infections (culturally proven,
other than cannula infection) occurred in 17 patients
(45%). The total number of infections was 35 per
1000 treatment months, based on 766 total months on
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Table 1. Patient data
Patient Age, Interval Blood Transfusions Dialysis at time Type of Dialyzer
No. sex Diagnosis months type N of anti-N0 dialyzer reuse
I 67F Analgesic
nephropathy
20 MM 5 Home D4 Kiil +
2 47M GN 22 MN 4 Satellite Dow4 0
3 59F Polycystic 12 MM 0 Home training D4 Kiil +
4 56F Hypertensive IS MN 7 Center D4, D3 Ku! 0
5 48F Polyarteritis 22 NN Multiple Home Dow4 +
6 47F Polycystic 8 MN 5 Center D4 Ku! 0
7 22M GN 21 MN Multiple Center D4, D3 Kiil 0
8 52M Polycystic 33 MN II Home Gambro, D4 +
9 61F Undetermined 11 NN Multiple Center D4 Kiil 0
10 3SF Diabetic 31 MM 22 Home Dow,Gambro,D4 +
II 52F Diabetic 8 NK Center D4 KijI 0
12 48F Polycystic 11 MN NK Home D4 Kiil +
13 51F Undetermined 11 MN 5 Home Dow, D4, Kiil +
14 46F CPN 21 MM 2 Center D4 Kiil 0
IS 6lM Polycystic 31 MN 2 Satellite D4 Kiil (+)
16 56F GN 13 MM None Home Gambro, Dow +
17 54F Polycystic 11 MN None Center D4 Kill 0
18 31M GN 11 MN NK Satellite Dow4 0
19 68F CPN 26 NN 5 Center D4 Kiil 0
20 67M GN 21 MN 2 Center D4, D3 Kiil 0
21 49F Stag horn calculi 13 MN 4 Center D4 Kiil 0
22 30M Diabetic 18 MN 4 Center D4 Kiil 0
23 60F Diabetic 10 2 Center D4 Kiil 0
24 44F CPN 9 MN 10 Center D4 Kiil 0
25 61M CPN 26 MN 2 Home D4Kiil +
26 5lM Polycystic 14 NN None Center Kiil 0
27 51F Polycystic 7 MN None Center D4 Kiil 0
28 55M Amyloidosis 37 MN 5 Home Gambro, D4, Kill +
29 52M GN 27 MM 3 Home Ku! +
30 47F GN 24 MM 3 Home D3,Kiil,Dow4 +
31 40M Polycystic 42 MN Multiple Home D4 Kiil +
32 7lM Nephrosclerosis 15 MN None Satellite Dow 4 0
33 64F Unknown 18 MN Nk Center D4 Kiil 0
34 5SF GN 16 MM I Home Dow4 +
35 45F Lupus 29 MM 2 Satellite Dow4 (+)
36 58F CPN 59 MN 10 Center D4, Kiil, Gambro 0
37 72M Undetermined 13 NN NK Satellite D4, D3 Kiil 0
38 63F CPN 19 MM Multiple Center D4 Kiil 0
(+), dialyzer reuse prior to anti-N0; GN, glomerulonephritis; CPN, chronic pyelonephritis.
dialysis prior to the development of anti-ND?. In 12
of these 17 patients, an episode of bacterial infection
appeared to be temporally related to the development
of anti-ND?. Six patients had septicemia (Escherichia
co/i, 1; Enierobacter, 1; A chromobacter, 1; Staphylo-
coccus aureus, coagulase-positive, 3) from infected
kidneys (patient 8) or cannula infection (patients 9,
16, 20, 29 and 34) at the time the antibody was
detected. In six other patients other forms of severe
infection were present immediately prior to or at the
time at which anti-NDP developed.
Table 2. MN phenotypes on 34 patients
MM MN NN
N 10 20 4
Observed, % 29 59 12
Expected, % 28 50 22
The majority of patients appeared to tolerate the
presence of anti-ND? without evidence of destruction
of their own red blood cells. The direct anti-globulin
test (DAT) result was usually negative. Evidence of
hemolysis was observed in 11 patients including 3
patients with severe infection. The fall in hemoglobin
concentration in patient 29 associated with sepsis and
the development of anti-NDP is shown in Fig. 4.
Patient 16 developed an acute reduction in hemoglo-
bin concentration from 9.2 to 6.2 g/lOO ml associated
with an Achromobacter septicemia. Patient 34 showed
evidence of mild hemolysis with a fall in hemoglobin
from 7.5 to 5.7 g/l00 ml and a reticulocytosis of 4.8%
during an episode of staphylococcal septicemia.
In eight patients hemolysis occurred at the time at
which anti-ND? was first detected in the absence of
sepsis. In patient 15, the fall in hematocrit value
associated with development of anti-N0p is shown in
Fig. 2. The reticulocytosis, rise in bilirubin concentra-
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Fig. I. Progressive drop in anti-N0 titer noted in this patient follow-
ing kidney transplantation.
tion, presence of spherocytes in the peripheral blood
and a haptoglobin concentration of 4 mg/100 ml
were suggestive of a hemolytic episode. Evidence of
hemolysis disappeared in two weeks and there were
no further problems of this type. Patient 19 had evi-
dence of a microangiopathic hemolytic anemia with a
fall in hemoglobin from 8.9 to 6.3 g/l00 ml, a retic-
ulocytosis of 12% and numerous fragmented cells on
the peripheral smear at the time at which HB8Ag-
positive hepatitis developed. One year later anti-ND?
was detected for the first time and was associated
with a recurrence of acute hemolysis. At this time
hemoglobin fell from 8.5 to 3.7 g/lOO ml, reticulocyte
counts ranged from 14 to 21% and nucleated red
blood cells and spherocytes were noted on peripheral
smear. This hemolytic episode cleared spontaneously
and she has had no further difficulty.
In three cases (patients 7, 13 and 14) there was
evidence of milder hemolysis near the time anti-ND?
was initially detected with drops in hemoglobin of 2
to 4.5 g/l00 ml and associated reticulocyte elevations
of 6 to 12%. Spherocytes and occasional nucleated
red blood cells were noted in peripheral smears.
A warm autoimmune hemolytic anemia developed
in one patient (37) at about the time anti-ND? was
detected. Over a two-month period he developed a
progressively more severe hemolytic anemia with the
hematocrit value falling from 30 to 12.0% during this
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Fig. 2. Development of anti-NDP over two years after leaving home
dialysis and switching to a satellite unit. Possible hemolysis was
noted at the time anti-Nap developed.
time, associated with a reticulocytosis of 14.8%, a
bilirubin rise to 2.2 mg/lOO ml and nucleated red cells
in the peripheral blood. Eventually the DAT became
positive and anti-ND? was detected. An eluate ini-
tially demonstrated anti-rh1 (C) and anti-hr'1 (e) spe-
cificity, but later demonstrated broader Rh specific-
ity, reacting with all cells except Rh null cells. Results
of 51Cr red blood cell survival determinations are
shown in Table 4, Survival of his own cells was deter-
mined one day following transfusion of 2 U of R,r
MM blood. On the basis of these studies, it appeared
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Table 3. Location of dialysis at time anti-N0 detected
Total No Reuse of Dialyzers Dialyzer Reuse at Some Time
patients
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Fig. 3. Increase in anti-N0 p titer noted in this patient for 35 months
after leaving home dialysis and switching to a satellite unit.
that the anti-Rh antibodies were clinically more im-
portant than the anti-ND?. Following treatment with
steroids and splenectomy, this patient has improved.
One further patient (3) had a DAT-positive hemoly-
tic anemia due to an antibody with broad Rh specific-
ity.
In patient 31 chronic problems in maintaining an
adequate hemoglobin level have been encountered.
When anti-ND? was initially detected, his hemoglobin
concentration was 4.0 g/lOO ml. Red blood cell sur-
vival revealed a t value of 6.5 days with marked
evidence of splenic sequestration. Following sple-
nectomy, however, his hemoglobin has ranged from
3.7 to 5.7 g/lOO ml and he has continued to require
transfusions for four years.
In one patient (14) it was necessary to use MN
blood for transfusion. Three months after renal allo-
transplantation, the patient was found at laparotomy
to have a ruptured pancreatic pseudocyst. Four days
later she began to hemorrhage from intercostal ves-
sels and went into profound shock. Because of short-
age of 0 Rh neg N neg blood at the time, she received
7 U of 0 Rh neg MN blood, which she tolerated well.
Two days postoperatively anti-ND? was still detect-
able, and she was typed strongly MN, indicating
survival of transfused cells. The DAT was negative.
The hemoglobin concentration postoperatively was
13.2 g/l00 ml and dropped to 9.6 g/100 ml the fol-
lowing day where it persisted for the next four days.
The bilirubin concentration rose to 2.5 mg/l00 ml
immediately postoperatively and dropped to 1.6
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Fig. 4. Multiple infections episodes noted in this patient. Hemolysis
occurred at the time anti-NDP was detected.
Case 29 mg/l00 ml the following day. She had chronic active
hepatitis (HB8Ag-positive) and later in her course the
bilirubin progressively rose. Urine output and blood
urea nitrogen (BUN) and creatinine concentrations
remained at preoperative levels for one week. At that
time she became septic, the infection did not respond
to antibiotics and she died two weeks later. At au-
topsy the kidney showed signs of chronic rejection
and some tubular necrosis.
Antibody detection. Generally, anti-ND? is detected
in the saline immediate spin phase of the antibody
______________________________
screening test. When panels are performed the saline
immediate spin phase and saline room temperature
phase usually demonstrate a characteristic anti-N
______________________________
pattern. In a few patients, some heterozygous (MN)
__________________________________ cells do not react and interpretation is difficult. If the
panels are incubated at 16 to 18°C, however, a typical
0 10 20 30 40 anti-N pattern is obtained, with the homozygous N
Months cells reacting more strongly than the heterozygous
cells. One of the strongest antibodies had a titer of
1:256 with homozygous cells and 1:16 with hetero-
zygous cells. The difficulty with interpreting a panel
at 16 to 18°C is that the cold reactive anti-I often
begins to react as well, producing agglutination of all
panel cells without any apparent pattern. We have
found if we treat the patient's red blood cells drawn
in EDTA anticoagulant with papain or ficin and use
these cells to absorb the serum at 4°C, that most or all
of the anti-I is removed and this adsorbed sera then
gives a typical anti-N pattern at 16°C. The enzymes
enhance the I reactivity of the red cells and decrease
the M and N antigens, so that even if a patient is NN
these enzyme-treated cells will not remove the anti-
ND?. Such adsorbed sera is ideal for crossmatching.
In MN and NN patients, the auto control is often
positive at room temperature and 18°C. Most MM
patients have negative auto controls.
Though anti-NOP does not usually react in the
warm (37°C) phases of screening, some strong anti-
N's reacted with NN cells in the albumin phase at
37°C. Only three anti-NDP's reacted in the antiglobu-
un phase with homozygous N cells. These three anti-
bodies were from patients whose phenotype was
MM.
Table 4. Survival of blood with varying Rh and MN
phenotypes in patient 37
Rh MN t½,days
R1R1 MM 3.9
R2R2 NN 7.5
R2R2 MM 10
Auto (R1r) NN 4
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Discussion
Anti-NDP in patients treated by regular hemo-
dialysis has recently been reported from several cen-
ters. Howell and Perkins [6] screened 416 patients,
finding anti-NDP in 12 (3%). McLeish, Brathwaite
and Peterson [8] detected anti-NDP in 6 of 40 dialysis
patients (15%) compared to 38 of 430 (9%) in the
present study. Since anti-N is rare in the general
population, the relatively high incidence in patients
with chronic renal disease treated by regular hemo-
dialysis suggests a causal relationship.
Howell and Perkins found that the incidence was
higher in men, whereas in our own series there were
more women than men who developed the antibody.
The age range of our patients is similar to that in
previous reports [6—8], and represents the age range
of patients maintained on long-term hemodialysis.
The distribution of M and N phenotypes is similar to
that reported in other dialysis programs (Table 2).
The increased incidence of anti-NDP in patients
with polycystic disease in our patients (24%) is similar
to the experience of McLeish et al [8] who reported
that 50% of their patients with anti-NDP had poly-
cystic kidneys. Howell and Perkins found that only
8% of their group of patients had polycystic kidney
disease [6]. The possibility that cystic fluid might
contain an antigen that is cross-reactive with the N
antigen needs further investigation.
In their study Howell and Perkins suggested that
the development of anti-NDP might be related to
dialyzer reuse [6]. They postulated that residual red
blood cells remaining in the dialyzer after cleaning
and resterilization might be altered by formaldehyde
causing them to become immunogenic. Harrison et al
[7] found anti-N0 in 45% of their home dialysis
patients, and did not detect anti-NDP in any patients
dialyzed in an outpatient facility who were not reus-
ing dialyzers. White, Miller and Kuehny [9] recently
reported the presence of anti-NDP in 24% of patients
dialyzed in outpatient facilities where formaldehyde
was used for sterilization, while anti-NDP was not
detected in patients treated in outpatient facilities
using coil dialyzers (ethylene oxide sterilization). All
of the patients developing anti-Nap in their study,
however, had reused dialyzers for at least five
months. These later studies, however, although sup-
porting Howell and Perkins' original theory, are in
conflict with our findings that 55% of patients devel-
oping anti-NDP have never reused dialyzers. The
patients developing anti-NDP all used dia!yzers which
were sterilized by formaldehyde, suggesting that for-
maldehyde per se and not reuse is possibly a causative
factor. Although the dialyzers are carefully rinsed
prior to the initiation of hemodialysis to remove for-
maldehyde, the usual reagent used to test for the
presence of formaldehyde (Clinitest) is relatively in-
sensitive to low formaldehyde concentrations.
Other possibilities that might induce development
of anti-NDP have been investigated. Though 19
patients with anti-ND p have had bovine fistulae, the
anti-NDP was present prior to insertion of the fistula
in seven patients suggesting that the bovine fistula is
not related to the development of anti-Nap. Further-
more, one patient had a bovine fistula in place for
more than a year without developing anti-NDP, but
developed the antibody one year after the shunt was
removed. The development of anti-NDP in five
patients in whom there is no record of prior trans-
fusions or pregnancies suggests that prior heterol-
ogous red blood cell exposure is not necessary for the
development of the antibody.
Generally, in our experience, once anti-N has
developed it has persisted, although the titer fluc-
tuates and the antibody may only be detectable at 16
to 18°C. An exception to the persistence of the an-
tibody has been seen in one transplant patient in
whom the antibody was no longer detectable one year
after transplantation. In one other patient the titer
dropped from 1:32 to 1:4 five months after she re-
ceived a renal allograft. Howell and Perkins [6] sim-
ilarly observed that the antibody either decreased in
titer or disappeared after transplantation.
The M and N antigens depend on sugar moities for
their antigenic specificity and are a part of a major
glycoprotein which can be extracted from the red
blood cell membrane by various methods [11, 12].
This glycoprotein contains sialic acid which appears
to be important in determining M and N specificity
[13, 14]. Springer, Tegtmeyer and Huprikar have
demonstrated that mild acid hydrolysis of the glyco-
protein from MM red blood cells, which removed
about one-half of the sialic acid (NANA), converts it
to a substance with N antigen specificity. Removal of
the rest of the sialic acid destroys N reactivity but
leaves a glycoprotein that still reacts strongly with the
lectin from Vicia graminea, a lectin generally consid-
ered to have anti-N activity. On the basis of these
types of studies, Springer et al have proposed the
following pathway for the development of M and N
specificity:
Precursor Vicia f NANA NN + NANA MM13
—3..
His studies indicate that anti-N made in rabbits rec-
ognizes an antigenic structure intermediate in the
biosynthetic pathway between that recognized by
Vicia lectin and that recognized by routine human
anti-N [13, 14].
White and co-workers have recently demonstrated
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that MM red blood cells incubated in 1.5% formal-
dehyde in vitro will become reactive with anti-ND?
but not rabbit anti-N [9]. This incubation mixture
was designed to mimic the conditions of resteriliza-
tion of dialysis membranes in their center. Though
they did not check these cells with Vicia, these results
would suggest that anti-N0 is recognizing an anti-
genic site different from that recognized by rabbit
anti-N which might be similar to that recognized by
the Vicia lectin. If this is the case, perhaps the normal
M and N antigens are being altered in some way
during dialysis, most likely by removing sialic acid,
exposing a site similar to the Vicia graminea site
which normally is "covered up," making it immuno-
genic. Anti-ND? would then be an antibody made to a
recently exposed antigen, which happens to give a
reaction pattern similar to that given by the more
standard anti-N antibodies.
Another mechanism by which sialic acid could be
removed is through the action of neuraminidase re-
leased by microorganisms. Though bacterial in-
fections occurred frequently in patients with anti-
the incidence was not significantly higher than
the incidence of infection in our total dialysis popu-
lation during the same period [151. The incidence of
serious infections in the patients with anti-ND? was 35
per 1000 treatment months prior to the development
of anti-NDP, while the incidence in our total dialysis
population is 30 per 1000 treatment months. Thus,
although the temporal relationship of serious bacte-
rial infections and anti-ND? detection is interesting,
our study does not support the concept that bacterial
infections are causally related to the development of
anti-ND?.
The development of two cases of DAT-positive
autoimmune hemolytic anemia with antibodies hav-
ing broad Rh specificity is of interest. It is possible
that in these patients the antibodies are directed
against an antigen occurring early in the biosynthetic
pathway of the Rh antigens which also becomes "un-
covered" by a mechanism similar to the proposed
mechanism responsible for "uncovering" the Vicia
graminea-like site. The progression of antibody spe-
cificity observed in one patient from anti-rh' (C) and
anti-hr" (e) to an antibody with broad Rh specificity
would support this concept. If antibodies are devel-
oping in dialysis patients to several different altered
or "newly uncovered" red blood cell antigens, it is
important to try to avoid the red cell membrane
damage which leads to the development of these anti-
bodies.
Anti-ND? is usually detected in the saline room
temperature phase of screening. Frequently, how-
ever, the pattern of reactivity with panel cells is in-
conclusive at room temperature, and the typical anti-
N reactivity is only seen when the incubation is car-
ried out at 16 to 18°C. Because these antibodies
persist with fluctuating titer, it is important that ade-
quate records be maintained and previously positive
patients tested at lower temperatures.
Another cold-reactive antibody, anti-I, is also of-
ten detected at this temperature, giving a weak reac-
tion with homozygous adult MM cells but not fetal
cord MM cells. In fact, we have observed that the
strength of anti-I often increased greatly as the anti-
ND? develops. At times, the anti-I reactivity is so
strong that it obscures the anti-ND?. Under these
circumstances, we have found that the anti-I can be
adsorbed at 4°C from the serum using the patient's
own cells treated with papain or ficin without affect-
ing the anti-NDP reactivity.
The clinical significance of anti-ND? is unknown.
In two patients documented hemolytic anemia was
temporally related to the development of anti-ND?
and hemolytic episodes probably occurred in nine
others. In both of the first two cases, the patients'
cells reacted with their own serum at room temper-
ature and 18°C but their DAT findings were negative.
Dialysis patients developing unexplained hemolytic
episodes should be checked for the presence of anti-
ND?. Although patients with anti-ND? should receive
N-negative blood when possible, the transfusion of
7 U of MN blood to one patient was well tolerated
clinically with only a mild fall in hemoglobin and
mild elevation of serum bilirubin concentration.
There have been several reports of immediate fail-
ure of renal allografts in patients with anti-NDP if the
graft is less than 30°C [6, 16]. Because of this danger,
it is important that transplant surgeons be aware of
the existence of anti-NDP in potential allograft recipi-
ents so that the allograft can be prewarmed prior to
transplantation [17]. Furthermore, it has been sug-
gested that red blood cell agglutination might occur
in dialysis lines when the temperature drops causing
difficulty with dialysis in patients with anti-ND? [71.
Reprint requests to Dr. John T. Crosson, Department of Pathol-
ogy. Hennepin County Medical Center, 701 Park A venue South,
Minneapolis, Minnesota 55415, U.S.A.
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